Identification of actin cytoskeleton organization genes in oral cancer and oral potentially malignant disorders using oral tissue RNA-seq database

  1. Serna-García, M. 1
  2. Formaggio, A. 1
  3. Carceller, MC. 23
  4. Romero, JJ. 4
  5. Flacco, N. 1
  1. 1 Universidad Europea de Valencia, Faculty of Health Sciences, Department of Dentistry, Valencia, Spain
  2. 2 Department of Pharmacy, Pharmaceutical Technology and Parasitology, Faculty of Pharmacy and Food Sciences, University of Valencia, Burjassot, Valencia, Spain
  3. 3 Interuniversity Research Institute for Molecular Recognition and Technological Development (IDM), University of Valencia, Polytechnic University of Valencia, Burjassot, Valencia, Spain
  4. 4 Igenomix S.L., Valencia, Spain
Show affiliations +
Journal:
Medicina Oral Patología Oral y Cirugia Bucal
  1. Marta Serna-García
  2. Agnese Formaggio
  3. María Carmen Carceller
  4. Joaquín Javier Panadero Romero
  5. Nicla Flacco

ISSN: 1698-6946

Year of publication: 2025

Pages: 0-0

Type: Article

DOI: 10.4317/MEDORAL.27364 GOOGLE SCHOLAR lock_openOpen access editor HANDLE: https://hdl.handle.net/11268/16089

More publications in: Medicina Oral Patología Oral y Cirugia Bucal

Abstract

Background: Oral cancer and oral potentially malignant disorders (leukoplakia and oral submucous fibrosis) are prevalent and clinically significant oral diseases. Actin, crucial for epithelial tissue integrity, undergoes cytoskeleton reorganization associated with increased invasiveness in oral cancer.Material and Methods: Bioinformatic analysis of RNA-seq data from GEO public databases was performed to detect differentially expressed genes in oral cancer, leukoplakia and oral submucous fibrosis. Enrichment analysis of the differentially expressed genes was performed using DAVID and GSEA softwares. ROC curve and survival analysis were conducted to assess the discriminative capacity of these genes as possible biomarkers. The results were further validated using RNAseq data from The Cancer Genome Atlas (TCGA).Results: EPRS1 was consistently overexpressed in all three pathologies. Key genes (ACTIN1, LIMK1, CORO1C, INF2, SH3D21, CFL1, FSCN1, MYO1B) implicated in actin cytoskeleton organization were identified, suggesting their role in oral potentially malignant disorders and cancer progression. Receiver operating characteristic (ROC) curves on 522 TCGA samples demonstrated these genes' potential as early biomarkers for oral cancer, with their inhibition associated with improved survival.Conclusions: The identified genes offer insights into actin-related mechanisms and potential pathways for the diagnosis and treatment of oral cancer. Nonetheless, further research is essential to validate these results.

Bibliographic References

  • 1. Pollard TD, Cooper JA. Actin, a central player in cell shape and movement. Science. 2009;326:1208-12.
  • 2. Ivanov AI, Hunt D, Utech M, Nusrat A, Parkos CA. Differential roles for actin polymerization and a myosin II motor in assembly of the epithelial apical junctional complex. Mol Biol Cell. 2005;16:2636-50.
  • 3. Lamouille S, Xu J, Derynck R.Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 2014;15:178. 4. Yamaguchi H, Condeelis J. Regulation of the actin cytoskeleton in cancer cell migration and invasion. Biochim Biophys Acta. 2007;1773:642.
  • 5. Aseervatham J. Cytoskeletal Remodeling in Cancer. Biology (Basel). 2020;9:1-40.
  • 6. Zhou S, Zhu Y, Li Z, Zhu Y, He Z, Zhang C. Exosome-derived long non-coding RNA ADAMTS9-AS2 suppresses progression of oral submucous fibrosis via AKT signalling pathway. J Cell Mol Med. 2021;25:2262-73.
  • 7. Tuch BB, Laborde RR, Xu X, Gu J, Chung CB, Monighetti CK, et al. Tumor transcriptome sequencing reveals allelic expression imbalances associated with copy number alterations. PLoS One. 2010;5:e9317.
  • 8. Xu S, Song Y, Shao Y, Zhou H. Comprehensive analysis of circular RNA in oral leukoplakia: upregulated circHLA-C as a potential biomarker for diagnosis and prognosis. Ann Transl Med. 2020;8:1375-75.
  • 9. Law CW, Alhamdoosh M, Su S, Smyth GK, Ritchie ME. RNA-seq analysis is easy as 1-2-3 with limma, Glimma and edgeR. F1000Res. 2016;5:1408.
  • 10. Hoo ZH, Candlish J, Teare D. What is an ROC curve? Emerg Med J. 2017;34:357-9.
  • 11. Khan K, Gogonea V, Fox PL. Aminoacyl-tRNA synthetases of the multi-tRNA synthetase complex and their role in tumorigenesis. Transl Oncol. 2022;19:101392.
  • 12. Kim S, You S, Hwang D. Aminoacyl-tRNA synthetases and tumorigenesis: more than housekeeping. Nat Rev Cancer. 2011;11:708-18.
  • 13. Son SS, Jeong HS, Lee SW, Lee ES, Lee JG, Lee JH, et al. EPRS1-mediated fibroblast activation and mitochondrial dysfunction promote kidney fibrosis. Exp Mol Med. 2024;56:2673-89.
  • 14. Lin LQ, Lv SY, Ren HZ, Li RR, Li L, Pang YQ, et al. Evodiamine inhibits EPRS expression to regulate glutamate metabolism and proliferation of oral squamous cell carcinoma cells. Kaohsiung J Med Sci. 2024;40:348-59.
  • 15. Kovac B, Mäkela TP, Vallenius T. Increased α-actinin-1 destabilizes E-cadherin-based adhesions and associates with poor prognosis in basal-like breast cancer. PLoS One. 2018;13:e0196986.
  • 16. Xie GF, Zhao LD, Chen Q, Tang DX, Chen QY, Lu HF, et al. High ACTN1 Is Associated with Poor Prognosis, and ACTN1 Silencing Suppresses Cell Proliferation and Metastasis in Oral Squamous Cell Carcinoma. Drug Des Devel Ther. 2020;14:1717-27.
  • 17. Villalonga E, Mosrin C, Normand T, Girardin C, Serrano A, Žunar B, et al. LIM Kinases, LIMK1 and LIMK2, Are Crucial Node Actors of the Cell Fate: Molecular to Pathological Features. Cells. 2023;12:805.
  • 18. Lagoutte E, Villeneuve C, Lafanechère L, Wells CM, Jones GE, Chavrier P, et al. LIMK Regulates Tumor-Cell Invasion and Matrix Degradation Through Tyrosine Phosphorylation of MT1-MMP. Sci Rep. 2016;6:24925.
  • 19. Shi B, Ma C, Liu G, Guo Y. MiR-106a directly targets LIMK1 to inhibit proliferation and EMT of oral carcinoma cells. Cell Mol Biol Lett. 2019;24:1.
  • 20. Kase-Kato I, Asai S, Minemura C, Tsuneizumi K, Oshima S, Koma A, et al. Molecular pathogenesis of the coronin family: Coro2a facilitates migration and invasion abilities in oral squamous cell carcinoma. Int J Mol Sci. 2021;22:12684.
  • 21. Ong MS, Deng S, Halim CE, Cai W, Tan TZ, Huang RYJ, et al. Cytoskeletal Proteins in Cancer and Intracellular Stress: A Therapeutic Perspective. Cancers (Basel). 2020;12:238.
  • 22. Heuser VD, Mansuri N, Mogg J, Kurki S, Repo H, Kronqvist P, et al. Formin Proteins FHOD1 and INF2 in Triple-Negative Breast Cancer: Association With Basal Markers and Functional Activities. Breast Cancer (Auckl). 2018;12:1178223418792247.
  • 23. Masoudi M, Seki M, Yazdanparast R, Yachie N, Aburatani H. A genome-scale CRISPR/Cas9 knockout screening reveals SH3D21 as a sensitizer for gemcitabine. Sci Rep. 2019;9:19188.
  • 24. Wang W, Eddy R, Condeelis J. The cofilin pathway in breast cancer invasion and metastasis. Nat Rev Cancer. 2007;7:429-40.
  • 25. Nishimura S, Tsuda H, Kataoka F, Arao T, Nomura H, Chiyoda T, et al. Overexpression of cofilin 1 can predict progression-free survival in patients with epithelial ovarian cancer receiving standard therapy. Hum Pathol. 2011;42:516-21.
  • 26. Turhani D, Krapfenbauer K, Thurnher D, Langen H, Fountoulakis M. Identification of differentially expressed, tumor-associated proteins in oral squamous cell carcinoma by proteomic analysis. Electrophoresis. 2006;27:1417-23.
  • 27. Zhang N, Gao Y, Bian Q, Wang Q, Shi Y, Zhao Z, et al. The role of fascin-1 in the pathogenesis, diagnosis and management of respiratory related cancers. Front Oncol. 2022;12:948110.
  • 28. Liu H, Hao W, Wang X, Zhang Y, He L, Xue X, et al. Identification of novel molecules and pathways associated with fascin actin bundling protein 1 in laryngeal squamous cell carcinoma through comprehensive transcriptome analysis. Int J Mol Med. 2024;53:39.
  • 29. Lii CK, Chang JW, Chen JJ, Chen HW, Liu KL, Yeh SL, et al. Docosahexaenoic acid inhibits 12-O-tetradecanoylphorbol-13- acetate-induced fascin-1-dependent breast cancer cell migration by suppressing the PKCδ- and Wnt-1/β-catenin-mediated pathways. Oncotarget. 2016;7:25162-79.
  • 30. Hopkins AM, Walsh SV, Verkade P, Boquet P, Nusrat A. Constitutive activation of Rho proteins by CNF-1 influences tight junction structure and epithelial barrier function. J Cell Sci. 2003;116:725-42.
  • 31. Sun Z, Guo X, Chen H, Ling J, Zhao H, Chang A, et al. MYO1B as a prognostic biomarker and a therapeutic target in Arecoline-associated oral carcinoma. Mol Carcinog. 2023;62:920-39.
  • 32. Chai AWY, Tan YH, Ooi S, Yee PS, Yee SM, Cheong SC. TNO155 is a selective SHP2 inhibitor to target PTPN11-dependent oral squamous cell carcinoma. Heliyon. 2024;10:e39677.
  • 33. Li B, Chen X, Xian H, Wen Q, Wang T. Gene mutation analysis of oral submucous fibrosis cancerization in Hainan Island. PeerJ. 2023;11:e16392.
  • 34. Zhao Y, Feng X, Zhao Y, Yang H, Zhang C. Overexpression of ST7-AS1 enhances apoptosis and inhibits proliferation of papillary thyroid carcinoma cells via microRNA-181b-5p-dependent inhibition of Tripartite Motif Containing 3. Mol Biotechnol. 2023;65:477-90.
  • 35. Zhuang L, Wang X, Wang Z, Ma X, Han B, Zou H, et al. MicroRNA-23b functions as an oncogene and activates AKT/GSK3β/βcatenin signaling by targeting ST7L in hepatocellular carcinoma. Cell Death Dis. 2017;8:e2804.
  • 36. Katoh M. Molecular cloning and characterization of ST7R (ST7- like, ST7L) on human chromosome 1p13, a novel gene homologous to tumor suppressor gene ST7 on human chromosome 7q31. Int J Oncol. 2002;20:1247-53